ICON Announces CFO Transition
ICON, a globally renowned healthcare intelligence and clinical research organization, has announced that its Chief Financial Officer, Brendan Brennan, will be stepping down from his position in the fourth quarter…
Read MoreICON Announces CFO Transition
Novartis to Seek Pre-Taxane Label Expansion for Pluvicto® in Second Half of 2024 Following Latest Data from Phase III PSMAfore Trial
Updated findings on overall survival (OS) from a planned evaluation, encompassing around 75% of data, reveal an OS hazard ratio below 1.0 (HR<1.0) within the intent-to-treat (ITT) population, not adjusted…
Imfinzi Boosts Survival in Limited-Stage Small Cell Lung Cancer: ADRIATIC Trial Results
AstraZeneca’s Imfinzi Shows Significant Improvement in Survival Rates for Limited-Stage Small Cell Lung Cancer Patients A recent Phase III trial, ADRIATIC, revealed promising outcomes for AstraZeneca’s Imfinzi (durvalumab) in treating…
Phase 3 Trial: Merck’s MK-1084 Oral KRAS G12C Inhibitor with KEYTRUDA® for Metastatic Non-Small Cell Lung Cancer
Merck, known as MSD outside of the United States and Canada, has announced the commencement of a Phase 3 clinical trial to evaluate MK-1084, an investigational oral selective KRAS G12C…
Bristol Myers Squibb Unveils 2023 Environmental, Social, and Governance Report: Highlighting Advancements and Establishing Future Objectives
Bristol Myers Squibb (NYSE: BMY) has unveiled its 2023 Environmental, Social, and Governance (ESG) Report, spotlighting significant progress, a refined strategy, and ambitious goals in its ESG initiatives. Rooted in…
EU Widens Approval for Bristol Myers Squibb’s Reblozyl® for First-Line LR-MDS Anemia
Bristol Myers Squibb (NYSE: BMY) has disclosed that the European Commission (EC) has broadened the approval of Reblozyl® (luspatercept) to encompass the initial treatment of adult patients grappling with transfusion-dependent…
US Accepts Biologics License Application for Datopotamab Deruxtecan in Advanced HR-Positive, HER2-Negative Breast Cancer Post-Prior Treatment
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been officially accepted in the United States. This application targets the treatment of adult patients grappling with…
WuXi Biologics Sweeps 2024 CDMO Leadership Awards Across the Board
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), trading as WuXi Bio (2269.HK), proudly announces its sweeping victory at the 2024 CDMO Leadership Awards. The company…
FDA Approves Astellas’ Supplemental New Drug Application for IZERVAY™ to Treat Geographic Atrophy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, referred to as “Astellas”) has received notification from the U.S. Food and Drug Administration (FDA) regarding the acceptance of the…
Eisai Seeks FDA Approval for IV Maintenance Dosing of LEQEMBI® in Early Alzheimer’s Treatment
Eisai Co., Ltd. (based in Tokyo, CEO: Haruo Naito) and Biogen Inc. (headquartered in Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) have jointly announced the submission of a Supplemental Biologics License…
Avian Influenza Epidemics in 2023
The recent occurrences of avian influenza outbreaks, observed last year, underscore the sobering reality of zoonotic influenza. These events emphasize that individuals of all ages are susceptible, regardless of comorbidities,…
Swine Influenza Outbreaks in 2023
Last year witnessed several outbreaks that underscore the reality of zoonotic influenza, revealing vulnerabilities across all age groups and highlighting the risks for individuals both with and without comorbidities. These…